How big is the UK Insulin Drugs And Delivery Devices Market?

The UK Insulin Drugs And Delivery Devices Market size is expected to reach USD 499.83 million in 2024 and grow at a CAGR of 1.9% to reach USD 549.15 million by 2029. Read More

What is the current UK Insulin Drugs And Delivery Devices Market size?

In 2024, the UK Insulin Drugs And Delivery Devices Market size is expected to reach USD 499.83 million. Read More

Who are the key players in UK Insulin Drugs And Delivery Devices Market?

Eli Lilly, Sanofi, Novo Nordisk, Medtronic and Ypsomed are the major companies operating in the UK Insulin Drugs And Delivery Devices Market. Read More

What years does this UK Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?

In 2023, the UK Insulin Drugs And Delivery Devices Market size was estimated at USD 490.51 million. The report covers the UK Insulin Drugs And Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the UK Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

UK Insulin Drugs & Delivery Devices Market

UK Insulin Drugs & Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers United Kingdom Insulin Drugs and Delivery Devices Market Manufacturers and it is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD million) and volume (in million mL) for insulin drugs and (in unit million) for the devices for the above segments.

UK Insulin Drugs & Delivery Devices Industry Overview

The United Kingdom Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.